INDERAL (propranolol hydrochloride) by Thayer Medical is clinical pharmacology general propranolol is a nonselective, beta-adrenergic receptor-blocking agent possessing no other autonomic nervous system activity. First approved in 1986.
Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
INDERAL (propranolol hydrochloride) is a nonselective beta-adrenergic receptor blocker used to treat hypertension, angina pectoris, arrhythmias, and migraine prophylaxis. It works by competitively blocking beta-adrenergic receptor sites, reducing heart rate, contractility, and blood pressure; at higher doses it exhibits quinidine-like membrane effects on cardiac action potential. The oral suspension formulation enables flexible dosing across cardiovascular and neurological indications.
Propranolol faces significant generic competition (30% competitive pressure rating) with LOE approaching, indicating shrinking commercial teams and transition from growth to maintenance-focused roles.
CLINICAL PHARMACOLOGY General Propranolol is a nonselective, beta-adrenergic receptor-blocking agent possessing no other autonomic nervous system activity. It specifically competes with beta-adrenergic receptor-stimulating agents for available receptor sites. When access to beta-receptor sites is…
Worked on INDERAL at Thayer Medical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer
Fasting Study of Propranolol Hydrochloride Extended-Release Capsules 160 mg and Inderal® LA Capsules 160 mg
Food Study of Propranolol Hydrochloride Extended-Release Capsules 160 mg and Inderal® LA Capsules 160 mg
Working on INDERAL positions professionals in mature-market, cost-driven pharmaceutical roles with emphasis on efficiency, pricing strategy, and volume management rather than innovation. Career progression requires transition to higher-growth therapeutic areas or advancement into corporate operations and strategy functions.